Circulating prognosis markers in melanoma: Proteomic profiling and clinical studies;Les marqueurs pronostiques circulants du mélanome : Profils protéomiques et études cliniques

Annales de Biologie Clinique

Volumn 69, Issue 2, 2011, Pages 151-157

  Solassol, Jérôme ^a   Guillot, Bernard ^b   Maudelonde, Thierry ^a  

^a HÔPITAL ARNAUD DE VILLENEUVE   (France)

^b MONTPELLIER UNIVERSITY HOSPITAL   (France)

Author keywords

Diagnosis; Melanoma; Prognosis; Proteome analysis

Indexed keywords

BIOLOGICAL MARKER;

ARTICLE; BLOOD; HUMAN; MELANOMA; PROGNOSIS; PROTEIN MICROARRAY; PROTEOMICS; SKIN TUMOR;

BIOLOGICAL MARKERS; HUMANS; MELANOMA; PROGNOSIS; PROTEIN ARRAY ANALYSIS; PROTEOMICS; SKIN NEOPLASMS;

EID: 79953894988     PISSN: 00033898     EISSN: 19506112     Source Type: Journal    
DOI: 10.1684/abc.2011.0523     Document Type: Article

References (34)

1. Belot A, Grosclaude P, Bossard N, Jougla E, Benhamou E, Delafosse P, et al. Cancer incidence and mortality in France over the period 1980-2005. Rev Epidemiol Sante Publique 2008 ; 56 : 159-75.
2. Balch CM, Buzaid AC, Soong SJ, Atkins MB, Cascinelli N, Coit DG, et al. Final version of the American joint committee on cancer staging system for cutaneous melanoma. J Clin Oncol 2001 ; 19 : 3635-48. (Pubitemid 32786276)
3. Aitchison TC, Sirel JM, Watt DC, MacKie RM. Prognostic trees to aid prognosis in patients with cutaneous malignant melanoma. Scottish Melanoma Group. BMJ 1995 ; 311 : 1536-9. [discussion 9-41]. (Pubitemid 3006428)
4. Becker D, Mihm MC, Hewitt SM, Sondak VK, Fountain JW, Thurin M. Markers and tissue resources for melanoma: meeting report. Cancer Res 2006 ; 66 : 10652-7. (Pubitemid 44876958)
5. Moore BW. A soluble protein characteristic of the nervous system. Biochem Biophys Res Commun 1965 ; 19 : 739-44.
6. Gaynor R, Irie R, Morton D, Herschman HR. S100 protein is present in cultured human malignant melanomas. Nature 1980 ; 286 : 400-1. (Pubitemid 10002887)
7. Zimmer DB, Cornwall EH, Landar A, Song W. The S100 protein family: history, function, and expression. Brain Res Bull 1995 ; 37 : 417-29.
8. Kruijff S, Bastiaannet E, Kobold AC, van Ginkel RJ, Suurmeijer AJ, Hoekstra HJ. S-100B concentrations predict disease-free survival in stage III melanoma patients. Ann Surg Oncol 2009 ; 16 : 3455-62.
9. Martenson ED, Hansson LO, Nilsson B, von Schoultz E, Mansson Brahme E, Ringborg U, et al. Serum S-100b protein as a prognostic marker in malignant cutaneous melanoma. J Clin Oncol 2001 ; 19 : 824-31. (Pubitemid 32119098)
10. Schultz ES, Diepgen TL, Von Den Driesch P. Clinical and prognostic relevance of serum S-100 beta protein in malignant melanoma. Br J Dermatol 1998 ; 138 : 426-30. (Pubitemid 28145509)
11. Hauschild A, Engel G, Brenner W, Glaser R, Monig H, Henze E, et al. S100B protein detection in serum is a significant prognostic factor in metastatic melanoma. Oncology 1999 ; 56 : 338-44. (Pubitemid 29240361)
12. Egberts F, Hitschler WN, Weichenthal M, Hauschild A. Prospective monitoring of adjuvant treatment in high-risk melanoma patients: lactate dehydrogenase and protein S-100B as indicators of relapse. Melanoma Res 2009 ; 19 : 31-5.
13. Stahlecker J, Gauger A, Bosserhoff A, Buttner R, Ring J, Hein R. MIA as a reliable tumor marker in the serum of patients with malignant melanoma. Anticancer Res 2000 ; 20 : 5041-4. (Pubitemid 32319076)
14. Hamberg AP, Korse CM, Bonfrer JM, de Gast GC. Serum S100B is suitable for prediction and monitoring of response to chemoimmunotherapy in metastatic malignant melanoma. Melanoma Res 2003 ; 13 : 45-9. (Pubitemid 36269813)
15. Smit LH, Korse CM, Hart AA, Bonfrer JM, Haanen JB,Kerst JM, et al. Normal values of serum S-100B predict prolonged survival for stage IV melanoma patients. Eur J Cancer 2005 ; 41 : 386-92. (Pubitemid 40187209)
16. Acland K, Evans AV, Abraha H, Healy CM, Roblin P, Calonje E, et al. Serum S100 concentrations are not useful in predicting micrometastatic disease in cutaneous malignant melanoma. Br J Dermatol 2002 ; 146 : 832-5. (Pubitemid 34539193)
17. Egberts F, Momkvist A, Egberts JH, Kaehler KC, Hauschild A. Serum S100B and LDH are not useful in predicting the sentinel node status in melanoma patients. Anticancer Res 2010 ; 30 : 1799-805.
18. Hill BR, Levi C. Elevation of a serum component in neoplastic disease. Cancer Res 1954 ; 14 : 513-5.
19. Agarwala SS, Keilholz U, Gilles E, Bedikian AY,Wu J, Kay R, et al. LDH correlation with survival in advanced melanoma from two large, randomised trials (Oblimersen GM301 and EORTC 18951). Eur J Cancer 2009 ; 45 : 1807-14.
20. Eton O, Legha SS, Moon TE, Buzaid AC, Papadopoulos NE, Plager C, et al. Prognostic factors for survival of patients treated systemically for disseminated melanoma. J Clin Oncol 1998 ; 16 : 1103-11. (Pubitemid 28108747)
21. Deichmann M, Benner A, Bock M, Jackel A, Uhl K, Waldmann V, et al. S100-beta, melanoma-inhibiting activity, and lactate dehydrogenase discriminate progressive from nonprogressive American joint committee on cancer stage IV melanoma. J Clin Oncol 1999 ; 17 : 1891-6. (Pubitemid 29269262)
22. MouawadR, Spano JP, Khayat D. Old and newserological biomarkers in melanoma: where we are in 2009. Melanoma Res 2010 ; 20 : 67-76.
23. Negrier S, Saiag P, Guillot B, Verola O, Avril MF, Bailly C, et al. Clinical practice guideline: 2005 update of recommendations for the management of patients with cutaneous melanoma without distant metastases (summary report). Bull Cancer 2006 ; 93 : 371-84.
24. Pons M, Mancheno-Corvo P, Martin-Duque P, Quintanilla M. Molecular biology of malignant melanoma. Adv Exp Med Biol 2008 ; 624 : 252-64.
25. Lescuyer P, Chevallet M, Rabilloud T. Concepts and therapeutic perspectives of proteomics. Med Sci (Paris) 2004 ; 20 : 587-92. (Pubitemid 38620604)
26. Greco M, Mitri MD, Chiriaco F, Leo G, Brienza E, Maffia M. Serum proteomic profile of cutaneous malignant melanoma and relation to cancer progression: association to tumor derived alpha-Nacetylgalactosaminidase activity. Cancer Lett 2009 ; 283 : 222-9.
27. Wilson LL, Tran L, Morton DL, Hoon DS. Detection of differentially expressed proteins in early-stage melanoma patients using SELDI-TOF mass spectrometry. Ann N Y Acad Sci 2004 ; 1022 : 317-22. (Pubitemid 38951619)
28. Findeisen P, Zapatka M, Peccerella T, Matzk H, Neumaier M, Schadendorf D, et al. Serum amyloid A as a prognostic marker in melanoma identified by proteomic profiling. J Clin Oncol 2009 ; 27 : 2199-208.
29. Diamandis EP. Mass spectrometry as a diagnostic and a cancer biomarker discovery tool: opportunities and potential limitations. Mol Cell Proteomics 2004 ; 3 : 367-78. (Pubitemid 38702090)
30. Gillette MA, Mani DR, Carr SA. Place of pattern in proteomic biomarker discovery. J Proteome Res 2005 ; 4 : 1143-54. (Pubitemid 41208673)
31. Li J, Orlandi R, White CN, Rosenzweig J, Zhao J, Seregni E, et al. Independent validation of candidate breast cancer serum biomarkers identified by mass spectrometry. Clin Chem 2005 ; 51 : 2229-35. (Pubitemid 41692564)
32. Zhang Z, Bast Jr. RC, Yu Y, Li J, Sokoll LJ, Rai AJ, et al. Three biomarkers identified from serum proteomic analysis for the detection of early stage ovarian cancer. Cancer Res 2004 ; 64 : 5882-90. (Pubitemid 39095590)
33. Pierce BL, Ballard-Barbash R, Bernstein L, Baumgartner RN, Neuhouser ML, Wener MH, et al. Elevated biomarkers of inflammation are associated with reduced survival among breast cancer patients. J Clin Oncol 2009 ; 27 : 3437-44.
34. Paulitschke V, Kunstfeld R, Mohr T, Slany A, Micksche M, Drach J, et al. Entering a newera of rational biomarker discovery for early detection of melanoma metastases: secretome analysis of associated stroma cells. J Proteome Res 2009 ; 8 : 2501-10.